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Abstract
Background/Aim. Amifostine (AMI) is a broad-spectrum
cytoprotector which protects against variety of radio- and
chemotherapy-related toxicities without decreasing their an-
titumor action. The aim of the study was to investigate the
potential protective effects of AMI against acute cardiotoxic
effects of doxorubicin (DOX) in male Wistar rats. Meth-
ods. AMI (300 mg/kg ip) was given 30 min before DOX (6
mg/kg and 10mg/kg b.w., iv). The evaluation of DOX-
induced cardiotoxic effects, as well as cardioprotective effi-
cacy of AMI was performed 48 h after their administration
by determining serum activities of enzymes known to be
markers of cardiac damage (creatine kinase – CK, aspartate
aminotransferase – AST, lactate dehydrogenase – LDH, and
its isoenzyme D-hydroxybutirate dehydrogenase – D-
HBDH), as well as the histopathological and ultrastructural
analysis of the heart tissue. Results. AMI successfully pre-
vented a significant increase in serum activity of CK, AST,
LDH and D-HBDH in animals treated with DOX in the
dose of 6 mg/kg (121.14 r 18.37 vs 167.70 r 44.24; 771.42
r 161.99 vs 1057.00 r 300.00; 3230.00 r 1031.73 vs 4243.10
r 904.06; 202.57 r 42.46 vs 294.90 r 80.20 UI/l, respec-
tively), and ameliorated DOX-induced structural damage of
the rat myocardium. Pretreatment with AMI in rats given 10
mg/kg DOX reduced the cardiac damage score (CDS) from
2.62 ± 0.51 to 1.62 ± 0.51, i.e. to the CDS value obtained
with the lower dose of DOX (6 mg/kg). The ultrastructural
analysis of the rat myocardium showed that AMI success-
fully protected the sarcolemma of cardiomyocytes and re-
duced mitochondria damage induced by DOX given in the
dose of 6 mg/kg. Besides, capillaries were less morphologi-
cally changed and apoptosis of endothelial cells was ex-
tremely rare in AMI-protected animals. AMI itself did not
cause any prominent changes in the examined parameters in
comparison with the control rats. Conclusion. AMI pro-
vided a significant protection against DOX-induced acute
cardiotoxic effects in rats. This finding implies its potential
to be a successful cardioprotector in patients treated with
DOX due to malignant diseases.
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Apstrakt
Uvod/Cilj.  Amifostin (AMI) je citoprotektor širokog
spektra koji može da spreÿi ispoljavanje toksiÿnih efekata
radio- i hemioterapije bez smanjenja njihovog antitumor-
skog dejstva. Cilj ove studije bio je ispitivanje efikasnosti
AMI u zaštiti od akutnih kardiotoksiÿnih efekata citostatika
doksorubicina (DOX) kod mužjaka Wistar pacova. Meto-
de.  AMI (300 mg/kg ip) davan je 30 min pre DOX (6
mg/kg i 10 mg/kg iv). Ispitivanje toksiÿnih efekata DOX,
kao i kardioprotektivne efikasnosti AMI sprovedeno je 48
sati nakon njihove primene. U tu svrhu odreĀivana je se-
rumska aktivnost enzima, koji su poznati kao markeri ošte-
ýenja miokarda (kreatin kinaze – CK, aspartat aminotransfe-
raze – AST, laktat dehidrogenaze – LDH, i njenog izoenzi-
ma D-hidroksibutirat dehidrogenaze – D-HBDH), i izvršena
je patohistološka i ultrastrukturna analiza tkiva miokarda.
Rezultati. Amifostin je uspešno spreÿio znaÿajno poveýanje
aktivnosti enzima CK, AST, LDH i D-HBDH u serumu ži-
votinja kojima je dat DOX u dozi od 6 mg/kg (121,14 r
18,37  vs  167,70  r 44,24; 771,42 r 161,99 vs 1057,00 r
300,00; 3230,00 r 1031,73 vs 4243,10 r 904,06; 202,57 r
42,46 vs 294,90 r 80,20 UI/l, redom), dok je kod pacova
koji su dobijali DOX u dozi od  10 mg/kg smanjio skor
ošteýenja miokada sa 2,62 ± 0,51 na 1,62 ± 0,51, odnosno
na vrednost skora dobijenu u grupi pacova sa nižom dozomVolumen 70, Broj 1 VOJNOSANITETSKI PREGLED Strana 39
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DOX (6 mg/kg). Ultrastrukturna analiza tkiva miokarda
pokazala je da je prethodna primena AMI kod pacova koji
su dobijali DOX u dozi od 6 mg/kg uspešno zaštitila sar-
kolemu kardiomiocita i smanjila ošteýenje mitohondrija i
kapilara, kao i pojavu apoptoze endotelnih ýelija. Sam AMI
nije izazvao nikakve znaÿajnije promene u ispitivanim para-
metrima u poreĀenju sa intaktnim (kontrolnim) pacovima.
Zakljuÿak. Amifostin ispoljava znaÿajan kardioprotektivni
efekat kod pacova u ranom periodu posle primene pojedi-
naÿnih visokih doza DOX. Ovaj nalaz ukazuje na potencijal
AMI da bude uspešan kardioprotektor i kod onkoloških
bolesnika koji primaju DOX.
Kljuÿne reÿi:
amifostin; doksorubicin; srce; lekovi, toksiÿnost; ýelija,
zaštita; pacovi, wistar.
Introduction
Doxorubicin (DOX), anthracycline antibiotic, is an im-
portant antineoplastic agent due to its high antitumor efficacy
in haematological, as well as in solid malignancies. How-
ever, adverse effects such as myelosuppresion and develop-
ment of irreversible cardiotoxicity, manifested as a dilated
cardiomiopathy leading to congestive heart failure, limit the
use of DOX 
1–4.
Although the molecular pathogenesis of DOX cardio-
toxicity is still controversial, oxidative stress-based hypothe-
sis involving intramyocardial production of reactive oxygen
species (ROS) has gained the widest acceptance 
5, 6. Namely,
drug toxicity may ensue through free-radical formation and a
subsequent redox cycle with O2, resulting in the generation
of ROS, such as superoxide anions (O2
.-), hydroxyl radicals
(OH
.) and hydrogen peroxide. The tissues with less devel-
oped antioxidant defenses, such as the heart, are particularly
susceptible to injury by DOX-induced oxygen radicals 
7, 8.
Cell membrane lipids are the most common substrates for
oxidative attack. Once initiated, peroxidation continues and
has a progressive course that results in structural and func-
tional changes in the heart tissue.
Since treating cardiac complications is very trouble-
some and expensive, a variety of efforts have been made to
reduce this cardiotoxicity without compromising the anti-
tumor activity of DOX 
9–11. One of them is the administra-
tion of the agent that would protect the myocardium from
DOX toxicity. Considering the aforementioned mechanism
of that toxicity, the approach based on the use of antioxi-
dants, including free radical scavengers, seems to be ra-
tional.
Amifostine (AMI) is a broad-spectrum cytoprotective
agent, with numerous preclinical and clinical studies sug-
gesting protection against a variety of radio- and chemother-
apy-related toxicities, including myelotoxicity, neurotoxicity
and nephrotoxicity, without decreasing the antitumor ac-
tion 
12–16. It is actually a prodrug that cannot protect tissues
until dephosphorylated by alkaline phosphatase in the plasma
membrane to the active metabolite, WR-1065. Once inside
the cell, its protective effects appear to be mediated by scav-
enging free radicals, hydrogen donation, induction of cellular
hypoxia, the liberation of endogenous nonprotein sulfhydrils
(mainly glutathione) from their bond with cell proteins, the
formation of mixed disulphides to protect normal cells etc.
Until now not too many reports have been published con-
cerning the prevention of DOX-induced cardiotoxicity by
AMI 
17–20.
The present investigation extended these studies. Serum
activity of enzymes, known to be markers of compromised
cardiomyocyte integrity and histological as well as ultra-
structural analysis (UA) of the myocardial tissue were used
to estimate the protective efficacy of AMI against DOX-
induced acute cardiotoxic effects in rats. High, single doses
of DOX, 6 mg/kg and 10 mg/kg b.w., were chosen by taking
into account the cumulative DOX dose (450 mg/m
2 body
surface or 11 mg/kg b.w.), known to produce potentially le-
thal cardiomiopathy in humans 
21.
Methods
Experimental animals and the protocol
Adult male Wistar rats weighing 200 g to 250 g were
used. The animals were housed in plastic cages, five animals
per cage, under standard laboratory conditions (room tem-
perature, 12/12 h light/dark cycle, free access to a standard
rodent chow and water).
The animals were divided into 6 experimental groups of
animals treated as follows:
The group I was the control one (saline, 1 ml/kg iv);
the group II was treated with AMI (300 mg/kg ip 30 min
before saline (1 ml/kg iv); the group III was treated with 6
mg/kg iv of DOX; the group IV was treated with 300 mg/kg
ip of AMI 30 min before DOX (6 mg/kg iv); the group V
was treated with 10 mg/kg iv of DOX and group the VI was
treated with 300 mg/kg ip of AMI 30 min before DOX (10
mg/kg iv).
The study was based on the Guidelines for Animal
Studies no 282-12/2002 (Ethics Committee of the Military
Medical Academy, Belgrade, Serbia).
Drugs
AMI was synthesized in the Chemical Department of
Military Technical Institute, Belgrade, by original procedure
based on the method described by Piper et al. 
22 , as already
published 
23. AMI was prepared for administration by dis-
solving the substance in sterilized and apyrogenic 0.9% NaCl
solution, ex tempore. DOX was obtained from commercial
sources (Adriblastina
®, Hemofarm, Vršac in colaboration
with Farmitalia Carlo Erba, Milan, Italy) and was dissolved
in the water supplied in the original drug package, immedi-
ately prior to injection.
Evaluation of myocardial toxicity and its prevention
Since earlier pathohistological studies have revealed
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after application of 6 and 10 mg/kg of DOX 
9, 24 we evalu-
ated the efficacy of the pretreatment with AMI on DOX-
induced cardiotoxicity within this period after their ad-
ministration, according to the study protocol. Blood sam-
ples were collected from the caudal vein, just before sac-
rifice by decapitation under light ether anaesthesia. Hearts
were removed rapidly and utilized for histopathological
analysis (HA). Each experimental group consisted of 8
animals.
Enzyme assays
Blood samples were centrifuged at 3.000 rpm for 10
minutes. The serum activity of creatine phosphokinase (CK),
aspartate aminotransferase (AST), lactate dehydrogenase
(LDH) and its isoenzyme D-hydroxybutyrate dehydrogenase
(D-HBDH) was determined on an autoanalyser Express 550
(Ciba Corning, Gilford Systems) using the test reagents pro-
duced by Randox firm (United Kingdom) and the procedures
recommended by the manufacturer.
Histopathological analysis
The removed hearts were fixed in 10% formalin.
Transmural tissue samples from the left and right ventricular
free walls were embedded in paraffin blocks. Tissue samples
5-ȝm thick were stained with haematoxylin & eosin (HE)
and heart sections were analyzed (20 x and 40x; Olympus-2
microscope; Tokyo, Japan). Grading of the cardiac tissue
damages and calculating the cardiac damage score (CDS)
were performed by using 0–3 scale as previously de-
scribed 
18, taking into account only myocytes showing cyto-
plasmic vacuolisation and/or myofibrillar loss. The grading
system was as follows: 0 = no damage; 1 = < 5% myocytes
damaged, 2 = 16%–25% myocytes damaged; 3 = > 35%
myocytes damaged. Per eight hearts from each group were
available, and per 5 sections from each heart were analyzed.
All morphological examinations were performed by 3 inde-
pendent observers as a blind study with no prior knowledge
of the treatment given to the animals.
Tissue Preparation and Electron Microscopy
Another experiment, according to the same study proto-
col, has been done for electron microscopy examination.
Immediately after the animals were sacrificed sections of the
myocardial tissue were taken from the free wall of the left
ventricle of each heart and small cubes of tissue were fixed
in cold 4% glutaraldehyde with  0.1M sodium cacodylate
buffer, at pH 7.2. After washing in the same buffer, the sam-
ples were postfixed with 1% osmium tetroxide, during 1 h,
on + 4C° and contrasted by uranyl acetate during 24 h. The
tissue was dehydrated in graded ethanol, transferred to pro-
pylene oxide and embedded in Epon. Sections were cut at 40
- 50 nm with a diamond knife on an LKB ultramicrotome,
stained with uranyl acetate and lead citrate, and examined
with a Philips 201 C electron microscope. Each experimental
group consisted of 5 animals.
Statistical analysis
The Student's t-test was used to asses differences in se-
rum enzyme activity. Statistical evaluation of the difference
in the severity of cardiac damage score among the various
treatment groups was performed by using the Kruskal-Wallis
rank test and Mann-Whitney U-test.
Results were considered significant when p < 0.05.
Commercial statistical software Stat for Windows,
R.4.5., Stat Soft Inc., Tulsa, OK, USA, 1993, was used
throughout the study.
Results
Effects of AMI on serum enzyme activity in
DOX-treated rats
The assessment of cardiomyocytes integrity in the
DOX-treated rats was done by determining the activity of
AST, ALT, LDH and its isoenzyme D-HBDH in the serum.
Serum activities of these enzymes were significantly in-
creased in animals treated with both doses of DOX (6 and 10
mg/kg iv) comparing to those of the control group (Figure 1).
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Fig. 1 – Influence of amifostine (AMI, 300 mg/kg ip) pretreatment on doxorubicin (DOX)-induced changes in aspartate ami-
notransferase (AST), creatine kinase (CK), lactate dehydrogenase (LDH) and D-hydroxybutyrate dehydrogenase (D-HBDH)
serum activity in rats 48 h after their administration (AMI was given 30 min before iv injection of DOX, 6 mg/kg or 10
mg/kg)
I – the control (saline, 1 ml/kg iv); II – AMI; III – DOX (6); IV – AMI +  DOX (6); V – DOX (10); VI – AMI +  DOX (10)
a* , a**, a*** – p < 0.05;  p < 0.01; p < 0.001 vs I; b* - p < 0.05 vs IIIVolumen 70, Broj 1 VOJNOSANITETSKI PREGLED Strana 41
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This increase was successfully prevented when animals were
given AMI prior to being treated with DOX in a dose of 6
mg/kg. However, in the group of animals treated with 10
mg/kg of DOX, AMI failed to prevent DOX-induced in-
crease of the serum activity of enzymes known to be markers
of cardiomyocytes integrity damage.
On the other hand, AMI given before saline injection
had no effect on the monitored parameters (Figure 1).
Effects of AMI on histopathological patterns of the
hearts in DOX-treated rats
Light microscopic examination of the myocardium
from DOX-treated rats in comparison with that of the con-
trol animals is shown in Figure 2. Histopathological analy-
sis of the heart tissue of rats given both tested doses of
DOX (6 mg/kg and 10 mg/kg) showed that most of the car-
diac muscle cells were regularly arranged. However, in
animals treated with 6 mg/kg of DOX a certain number of
cardiomyocytes with fine granular cytoplasm, without
clearly noticeable nuclei, was detected, some of which had
small vacuoles and/or pale appearance of the cytoplasm. In
animals pretreated with AMI just a small number of myo-
cytes with fine granular cytoplasm was seen differing from
surrounding normal myocardial tissue. The appearance of
numerous vacuoles and segmental loss of normal tissue
structure was seen in rats treated with 10 mg/kg DOX,
while in animals pretreated with AMI more preserved myo-
cardial structure was visible, with less extensive vacuoliza-
tion of cardiomyocytes (Figure 2). Grading cardiac tissue
damages by 0–3 scale in rats, treated with DOX in single
doses of 6 and 10 mg/kg,  revealed CDS of  1.62 r 0.51 and
2.62  r 0.51, respectively. The differences between the
control and DOX treated groups were statistically signifi-
cant (Table 1). In the group of rats treated with 6 mg/kg of
DOX which had previously received AMI, myocyte altera-
tions were significantly less severe than those observed in
animals without pretreatment (p < 0.01).  Pretreatment with
AMI in rats given DOX in a dose of 10 mg/kg reduced
CDS to the value obtained in the group of rats treated with
6 mg/kg of DOX (Table 1).
Fig. 2 – Light microscopy of the heart sections: (A) control group – myocardium of normal morphology, (B) group treated
with amifostine (AMI) – no histological lesions found (H&E, u40), (C) group treated with doxorubicin (DOX) 6 mg/kg –
small number of myocites with discrete vacuolization, (D) group treated with AMI + DOX 6 mg/kg – a small number of car-
diomyocytes with fine granular cytoplasm (H&E, u20), (E) group treated with DOX 10 mg/kg – appearance of numerous
vacuoles and segmental loss of normal tissue structure, (F) group treated with AMI + DOX 10 mg/kg – less extensive vacu-
olization of cardiomyocytes with more preserved myocardial structure (H&E, u40)
Table 1
The influence of amifostine on cardiac damage scores (CDS) in rats treated with doxorubicin
Cardiac damage score (CDS)**
(8 hearts x 5 section) Treatment (mg/kg)*
0123
Mean CDS ± SD
Control (saline, 1 ml/kg iv) 30 10 0 0 0.25 ± 0.46
AMI (300) 30 10 0 0 0.25 ± 0.46
DOX (6) 0 15 25 0 1.62 ± 0.51 
a
AMI (300) + DOX (6) 25 10 5 0 0.50 ± 0.75 
b
DOX (10) 0 0 15 25 2.62 ± 0.51 
a
AMI (300) + DOX (10) 0 15 25 0 1.62 ± 0.51 
a b
*Amifostine (AMI) was administered ip 30 min before doxorubicin (DOX) given iv; ** CDS: 0 – no damage; 1 – < 5% myocytes damaged;
2–16% to 25% myocytes damaged ; 3 – > 35% myocytes damaged; 
† Statistical evaluation was performed using Kruskal-Wallis test:
 a p <
0.001 vs control; Mann-Whitney U test:  
bp < 0.01 vs corresponding DOX groupStrana 42 VOJNOSANITETSKI PREGLED Volumen 70, Broj 1
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In animals sacrificed 48 h after giving AMI 30 min be-
fore saline (1 ml/kg iv) no any pathological changes were
found, nor CDS was significantly different from that of the
control group.
Effects of AMI on ultrastructural alterations of the
hearts in DOX-treated rats
Ultrastructural analysis (UA) of the heart sections of
rats treated with DOX in a dose of 6 mg/kg showed promi-
nent alterations comparing to those of the control rats (Figure
3a). Cardiomyocytes were transparent, with preserved vol-
ume. Nuclei of the cardiomyocytes had an altered shape,
with shallow invagination of nucleus membrane and en-
larged perinuclear spaces. Mitochondria were numerous, hy-
dropically degenerated with enlarged volume and light ma-
trix. Their cristae were moved to periphery (Figure 3b). Sar-
colemma of some cardiomyocytes were locally lysed and
mitochondria could be seen out of the cell, in intercellular
spaces. Endothelial cells in the capillaries between cardio-
myocytes showed changes that could be described as the
ones characteristic for programmed cell death – apoptosis.
These cells became very thin, with condensed, dark cyto-
plasm and heavily condensed chromatin filling the majority
of caryoplasma. (Figure 3c). In some biopsies rupture of
capillary walls could be seen.
In the animals which received AMI before DOX in-
jected in the same dose (6 mg/kg iv), structural changes were
prominently less expressed, with no lysis of cardiomyocytes
sarcolemma. Nuclei of myocytes were, most often, like those
in the control animals, while the mitochondria damage was
less prominent (Figure 3d). Capillaries were less morpho-
logically changed and apoptosis of endothelial cells was ex-
tremely rare.
The application of AMI itself, without DOX, led to dis-
crete changes of the  cardiomyocytes  comparing to the con-
trol animals. Shallow invagination of the nucleus membrane
and marginal condensation of heterochromatin were most
prominent. Mitochondria with lamellar cristae predominated
in this group of animals.
Discussion
The results of this study showed that the serum activity
of CK, AST, LDH and its isoenzyme D-HBDH, as the most
characteristic marker for cardiac damage, was significantly
increased in the animal groups treated with both doses of
DOX comparing to the control rats, in a dose- dependant
way. The elevation of serum concentrations of examined en-
zymes is a well-known quantitative index of compromised
cellular integrity, and is also considered to be a good indica-
tor of myocardial damage by DOX 
25–27. Formation of free
radicals and peroxidation of lipids of cardiomyocyte mem-
branes, including sarcolemma, caused by DOX, is thought to
be followed by membrane permeability and other changes of
membrane functions. Our findings are in accordance with the
results of other authors who showed that increased serum
activity of CK and LDH was detected in the period lasting
between a few hours and 4 days after the administration of
DOX doses ranging from 10 to 20 mg/kg, with the peak at
day 2 
10, 27, 28. It was considered that a damaged sarcolemma
enables the enzymes to pass out of the cell, thus accounting
for their prominent increase in the serum. This was actually
Fig. 3 – Electron micrograph of myocardium from: (A) control group of animals – control heart demonstrating normal
peripheral distribution of nuclear chromatin (nu), sarcomeres, and mitochondria (original magnification u36,000) (B) group
of animals treated with doxorubicin (DOX) 6 mg/kg – mitochondria (m) hydropically degenerated with enlarged volume and
light matrix (ĺ). Cristae are moved to periphery (original magnification u67,500). (C) group of animals treated with DOX 6
mg/kg – prominently thin capillary wall (ĺ); endothelial cell nucleus irregularly shaped with increased quantity of
heterochromatin () (original magnification u23,850) (D) group of animals treated with amifostine (AMI) + DOX 6 mg/kg –
mitochondria like in control animals, sarcolemma is preserved (ĺ), capillary endothelial cell nucleus with marginally
distributed heterochromatin () (original magnification u30,000)
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confirmed in our experiment in which the UA of the heart
sections of the rats treated with 6 mg/kg of DOX showed that
the sarcolemma of some cardiomyocytes was locally lysed
and mitochondria could be seen out of the cell, ie in inter-
cellular spaces.
On the other hand, HA revealed, taking into account
only myocytes showing cytoplasmic vacuolization and/or
myofibrillar loss, CDS of 1.62 r 0.51 and 2.62 r 0.51 in rats
treated with 6 mg/kg and 10 mg/kg of DOX, respectively.
The differences between the control and DOX-treated
groups were dose-dependent and  statistically significant.
The myocardial cellular alterations associated with the ad-
ministration of DOX in our experiments were similar to
those reported in previous experimental studies 
9, 24, 28, 29.
The affected myocytes displayed two characteristic light
microscopic changes: cytoplasmic vacuolization and/or
myofibrillar loss. The more myocytes showed these
changes, the more pronounced the lesions became. UA of
the rat heart 48 h after administration of 6 mg/kg of DOX
revealed cardiomyocyte alterations described as oncosis. In
parallel with the preserved volume and marginally con-
densed heterochromatin these cells had hydropically degen-
erated mitochondria with the light matrix and cristae moved
to periphery. This was in accordance with the results of
other authors who showed that the earliest and most often
changes in the rat heart after application of DOX high doses
were cellular oedema and swelling of the mitochondria in
cardiomyocytes 
28. It is widely accepted that oncosis, as a
type of prelethal changes, is characterized by the loss of cell
volume control, typically resulting from adenosine triphos-
phate (ATP) deficiency and subsequent failure of Na
+-
K
+ATPase at the plasmalemma, early clumping of nuclear
chromatin, swelling of the mitochondria and dilatation of
the endoplasmic reticulum (ER) and Golgi components 
30–32.
On the other hand, apoptosis is characterized by cell shrink-
age, accompanied by marked cell shape changes with multi-
ple cytoplasmic protrusions and nuclear irregularities with
intense chromatin clumping. The cytosol is electron-dense
though some ER dilatation and mitochondrial condensation
occur. Biochemically, there are both maintenance of ATP in
the cell and the increased level of Ca
2. In our experiments
apoptotic cardiomyocytes were not observed. That can be
explained by the fact that some special stainings, including
TUNEL assay, are necessary for their detection. Also, Arola
et al. 
29 showed that 2 days after ip injection of DOX in the
dose of 5 mg/kg only 0.033% of cardiomyocytes had
TUNEL-positive nuclei (comparing with 0.0065% in con-
trol). The current understanding of molecular mechanisms
underlying DOX-induced cardiomyocyte type of death, both
apoptosis and necrosis, still imply excessive production of
ROS. However, it is considered that predominant mecha-
nism of cell death is determined by DOX dosage. Namely,
low-dose DOX exposure induced apoptosis whereas high-
dose exposure primarily induced oncosis of myocytes 
5, 6, 33.
The latter corresponds to our experimental conditions. On
the other hand, UA revealed some capillary endothelial cells
with morphological changes characterizing apoptosis, in ac-
cordance with the results of other authors 
34–36.
AMI successfully prevented significant increase of se-
rum activity of all the examined enzymes in animals treated
with DOX in a dose of 6 mg/kg. In AMI protected animals
myocyte alterations were significantly less severe than those
observed in animals without pretreatment. Moreover, the
pretreatment with AMI in rats receiving higher dose of DOX
(10 mg/kg) reduced CDS to the value obtained in the group
of unprotected rats given 6 mg/kg of DOX. UA actually
showed that the pretreatment with AMI in rats receiving 6
mg/kg of DOX protected the sarcolemma of cardiomyocytes,
and significantly reduced mitochondria damage. Moreover,
in the protected rats myocardial capillaries were less mor-
phologically changed and apoptosis of endothelial cells was
extremely rare. AMI itself did not cause any changes in all of
the examined parameters in comparison with the control rats.
Previous  in vitro studies demonstrated that WR-1065, the
active metabolite of AMI, was able to scavenge OH
. and O2
.-,
including DOX-derived O2
.- generated by NADH respiration
of heart mitochondria particles 
37. Many studies still support
the hypothesis that mitochondria are a primary target of
DOX-induced oxidative stress. The fact that typical mito-
chondrial density per cell unit volume ranges from 25% to
35% in cardiomyocytes may partially explain why DOX is
selectively toxic to the heart 
38, 39. AMI is a negative charged
thiol which accumulates within the mitochondria and around
DNA. These facts explain higher protective potential of AMI
compared with that of neutral or positive charged thiols,
taking into account some studies using perfused rat hearts
which have shown that DOX is localized primarily arround
the nucleus and within cell mitochondria 
39, 40. Also, both
AMI and WR-1065 significantly reduce DOX-induced heart
cell toxicity, measured by ATP content, normalised to the
total cellular protein 
37. That can also be explained by their
effective protection of mitochondria, as in our study, since
oxidative phosphorylation is one of the functions of this or-
ganelae which provides a substantial portion of the ATP
needed to meet energy demands of the heart. On the other
hand, several lines of evidence suggest that AMI is presuma-
bly modified by membrane-bound alkaline phosphatase
which is highly expressed in the endothelium and transferred
into WR-1065. Then, WR-1065 quickly penetrates into cells,
and acts as free-radical scavenger protecting them from oxi-
dative damage 
13, 14, 41. Potent protective effects of AMI pre-
treatment in the model of pulmonary endothelial cell barrier
dysfunction in vitro were shown. Owing to AMI the attenua-
tion of oxidative stress, NF-țB inflammatory cascade and
disruption of endothelial cell adhesions leads to the preser-
vation of endothelial cell monolayer integrity 
42. On the other
hand, marked elevation of the expression of antioxidant en-
zyme manganese superoxide dismutase (MnSOD) gene in
human microvascular endothelial cells following their expo-
sure to a WR-1065 can result in elevated resistance to the
cytotoxic effects of ionizing radiation. Namely, MnSOD is
nuclear-encoded mitochondrial enzyme that scavenges O2
.-
in mitochondrial matrix, and has been shown to be highly
protective against radiation-induced ROS 
43. Based on the
current data, the present authors speculate that succesful
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whose endothelium as a rich source of oxidants contributes a
lot to the oxidant-rich environment at that locus in this
model, may be mediated by AMI antioxidant properties re-
sulting in downregulation of oxidative stress and redox-
sensitive signalling cascades. Bolman et al. 
19, 44 have shown
that AMI significantly decreases DOX-induced lipid peroxi-
dation (evaluated by malondialdehyde level) and increases
the levels of reduced gluthatione (GSH) and catalase activity
in the hearts of rats treated by high doses of DOX. According
to Luo et al. 
26, after the application of DOX, ROS by in-
ducing lipid peroxidation produce cytotoxic aldehydes re-
sulting in inflammatory reactions. This eventually leads to
increased synthesis of cytokines, infiltration of mononuclear
cells and death of cardiomyocytes. In accordance with this,
in our previous experiments the presence of mononuclear
cells and fibroblasts was decreased in AMI-protected rats
and necrotic myocytes were rare compared with DOX-only
treated group 
18. However, the high dose of DOX was a cu-
mulative one, given as a multiple, low, unitary dose regimen,
with AMI always preceding DOX. According to that, our
own results 
18, as well as some others' 
45, 46 support the state-
ment that acute and chronic cardiac toxicity of DOX share
the same mechanism, implying that chronic toxicity arises
from repeated episodes of acute exposure which induces a
cumulative damage. However, since single doses of DOX
used in this experiment were very high, AMI might produce
its cardioprotective effect by some other mechanisms, be-
sides the antioxidative one. For example, it has recently been
shown that AMI, given in doses similar to that used in this
experiment, produced a strong anti-inflammatory activ-
ity 
42, 47, 48 that might additionally offer protection against
DOX-induced cardiac damage. However, further investiga-
tions are needed to confirm this hypothesis.
Conclusion
In summary, the present study demonstrates the potent
protective effects of AMI pretreatment against acute cardio-
toxic effects of DOX given in single high doses in rats. The
obtained results imply the potential of AMI to be a success-
ful cardioprotector in patients treated by DOX due to malig-
nant diseases.
REFERENCES
1. Sweetman SC, editor. Martindale: The Complete Drug Refer-
ence 36 [CD-ROM]. London: Pharmaceutical Press; 2009.
2. Chabner BA, Alegra CJ, Curt GA, Calabresi P. Chemotherapy of
neoplastic diseases. In: Brunton LL, Lazo JS, Parker KL, editors.
Goodman & Gilman’s the Pharmacological Basis of Thera-
peutics. New York: McGraw-Hill; 2006: p. 1315–404.
3. Singal PK, Iliskoviý N. Doxorubicin-induced cardiomyopathy. N
Engl J Med 1998; 339(13): 900–5.
4. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic
agents. Incidence, treatment and prevention. Drug Safety
2000; 22(4): 263–302.
5. Šimunek T, Šterba M, Popelova O, Adamcova M, Hrdina R, Gerši
V. Anthracycline-induced cardiotoxicity: overview of studies
examining the roles of oxidative stress and free cellular iron.
Pharmacol Rep 2009; 61(1): 154–71.
6. Zhang Y, Shi J, Li Y, Wei L. Cardiomyocyte death in doxorubi-
cin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz)
2009; 57(6): 435–45.
7. Keizer HG, Pinedo HM, Schuurhuis  GJ, Joenje H. Doxorubicin
(adriamycin): a critical review of free radical-dependent
mechanisms of cytotoxicity. Pharm Ther 1990; 47(2): 219–31.
8. Papadopoulou LC, Theophilidis G, Thomopoulos GN, Tsiftsoglou AS.
Structural and functional impairment of mitochondria in
adriamycin-induced cardiomyopathy in mice: suppression of
cytochrome C oxidase II gene expression. Biochem Pharmacol
1999; 57(5): 481–9.
9. Tesoriere L, Ciaccio M, Valenza M, Bongiorno A, Maresi E, Albiero
R, et al. Effects of vitamin A administration on resistance on
rat heart against doxorubicin-induced cardiotoxicity and le-
thality. J Pharm Exp Ther 1994; 269(1): 430–6.
10. Dobriý S, Dragojeviý-Simiý V, Bokonjiý D, Milovanoviý S, Marinÿiý D,
Joviý P. The efficacy of Selenium, WR-2721, and Their Combi-
nation in the Prevention of Adriamycin-Induced Cardiotoxic-
ity in Rats. J Environment Pathol Toxicol Oncol 1998; 17(3–
4): 291–9.
11. Wouters K, Kremer L, Miller T, Herman E, Lipschultz S. Protecting
against anthracycline-induced myocardial damage: a review of
the most promising strategies. Br J Haematol 2005; 131(5):
561–78.
12. Dragojeviý-Simiý V, Dobriý S . The cytoprotective agent ami-
fostine (WR-2721): current clinical use and trends in its devel-
opment. Vojnosanit Pregl 1996; 53(4): 305–10 (Serbian)
13. Spencer CM, Goa KL. Amifostine: a review of its pharmacody-
namic and pharmacokinetic properties, and therapeutic poten-
tial as a radioprotector and cytotoxic chemoprotector. Drugs
1995; 50(6): 1001–31.
14. Capizzi RL. The preclinical basis for broad-spectrum selective
cytoprotection of normal tissue from cytotoxic therapies by
amifostine. Semin Oncol 1999; 26(2 Suppl 7): 3–21.
15. Culy CR, Spencer CM. Amifostine: an update on its clinical
status as a cytoprotectant in patients with cancer receiving
chemotherapy or radiotherapy and its potential therapeutic ap-
plication in myelodysplastic syndrome. Drugs  2001; 61(5):
641–84.
16. Kouvaris J, Kouloullas V, Vlahos L. Amifostine: The first Selec-
tive-Target and Broad-Spectrum Radioprotector. Oncologist
2007; 12(6): 738–47.
17. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart
H. Effects of amifostine on perfused isolated rat heart and on
acute doxorubicin-induced cardiotoxicity. Cancer Chemother
Pharmacol 1999; 43(3): 227–32.
18. Dragojeviý-Simiý V, Dobriý S, Bokonjiý D, Vucinic Z, Sinovec S, Jace-
vic V, et al. Amifostine protection against doxorubicin cardio-
toxicity in rats. Anticancer Drugs 2004; 15(2): 169–78.
19. Bolman Z, Cicek C, Kadikoylu G, Barutca S, Serter M, Yeniseu C, et
al. The Protective Effects of Amifostine on Adriamycin-
Induced Acute Cardiotoxicity in Rats. Tohoku J Exp Med
2005; 207(4): 249–53.
20. Potermski P, Polakowski P, Wiktorowska-Owczarek A, Owczarek J,
Pluzanska A, Orszulak-Michalak D. Amifostine improves he-
modynamic parameters in doxorubicin-pretreated rabbits.
Pharmacol Rep 2006; 58(6): 966–72.
21. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J
Med 1991; 324(12): 843–5.
22. Piper JR, Stringfellow CRJr, Eliot RD, Johnston TP. S-2-(omega-
aminoalkyl amino)ethyl dihydrogen phosphorothioates and
related compounds as potential antiradiation agents. J Med
Chem 1969; 12(2): 236–43.Volumen 70, Broj 1 VOJNOSANITETSKI PREGLED Strana 45
Dragojeviý-Simiý V, et al. Vojnosanit Pregl 2013; 70(1): 38–45.
23. Trajkoviý S, Dobriý S, Jaýeviý V, Dragojeviý-Simiý V, Milovanoviý Z,
đorĀeviý A . Tissue-protective effects of fullerenol C60(OH)24
and amifostine in irradiated rats. Colloids Surf B Biointerfaces
2007; 58(1): 39–43.
24. Griesser-Aleksiý N, Nikoliý V, Bogdanoviý G, Baltiý V, Spasiý M.
Prevention of doxorubicin cardiotoxicity with selenium. On-
kološki arhiv 1994; 2: 195–7 (Serbian)
25. Olson HM, Shannon CF. Alterations of lactate dehydrogenase
isoenzymes with subacute adriamycin toxicity. Cancer Treat
Rep 1979; 63(11–12): 2057–9.
26. Luo X, Evrovsky Y, Cole D, Trines J, Benson LN, Lehotay DC.
Doxorubicin-induced acute changes in cytotoxic aldehydes,
antioxidant status and cardiac function in rats. Biochem Acta
1997; 1360: 45–52.
27. Milic-Tores V, Srdjenovic B, Jacevic V, Dragojevic-Simic V, Djordjevic
A, Luisa Simplicio A. Fullerenol C60(OH)24 prevents doxorubi-
cin-induced acute cardiotoxicity in rats. Pharmacol Rep 2010;
62(4): 707–18.
28. Olson HM, Capen CC. Subacute cardiotoxicity of adriamycin in
the rat. Biochemical and ultrastructural investigations. Lab In-
vest 1977; 37(4): 386–94.
29. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinene M, Voipio-
Pulkki LM. Acute doxorubicin cardiotoxicity involves cardio-
myocyte apoptosis. Cancer Res 2000; 60(7): 1789–92.
30. Trump BF, Berezesky IK. Oncosis, apoptosis and necrosis: The
role of >Ca2+@i deregulation. Electron Microscopy 1998; IV:
811–2.
31. Maisch B. How cardiac cell die-necrosis, oncosis and apoptosis.
Herz 1999; 24(3): 181–8.
32. Buja LM, Vela D. Cardiomyocyte death and renewal in the
normal and diseased heart. Cardiovasc Pathol 2008; 17(6):
349–74.
33. L'Ecuyer T, Allebban Z, Thomas R, Vander Heide R. Gluthatione
S-transferase overexpression protects against anthracycline-
induced H9C2 cell death. Am J Physiol Heart Circ Physiol
2004; 286(6): H2057–64.
34. Zhang J, Clark JR, Herman EH, Ferrans VJ. Doxorubicin-
induced apoptosis in spontaneously hypertensive rats: dif-
ferential effects in heart, kidney and intestine, and inhibi-
tion by ICRF-187. J Mol Cell Cardiol 1996; 28(9): 1931–
43.
35. Kotamraju S, Konorev EA, Joseph J, Kalayanaraman B. Doxorubi-
cin-induced apoptosis in endothelial cells and cardiomyocytes
is ameliorated by nitrone spin traps and ebselen. J Biol Chem
2000; 275(43): 33585–92.
36. Warren MC, Bump EA, Medeiros D, Braunhut SJ. Oxidative
stress-induced apoptosis of endothelial cells. Free Rad Biol
Med 2000; 29(6): 537–47.
37. Marzatico F, Porta C, Moroni M, Bertorelli L, Borasio E, Finotti N,
et al. In vitro antioxidant properties of amifostine (WR-2721,
Ethyol). Cancer Chemother Pharmacol 2000; 45(2): 172–6.
38. Gille L, Nohl H. Analyses of the molecular mechanism of
adriamycin-induced cardiotoxicity. Free Rad Biol Med 1997;
23(5): 775–82.
39. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mito-
chondrial cardiotoxicity. Cell Biol Toxicol 2007; 23(1): 15–25.
40. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: current
status and new directions. Oncology 2002; 63(Suppl. 2): 2–10.
41. Dragojeviý-Simiý V, Dobriý S, Kilibarda V, Bokonjiý D, Milovanoviý S.
Cytoprotector amifostine (WR-2721): pharmacokinetic properties
and analytical methods for drug determination. Arch Toxicol Ki-
net Xenobiot Metab 1996; 4: 185–97.
42. Fu P, Birukova AA, Xing J, Sammani S, Murley JS, Garcia JG, et
al. Amifostine reduces lung vascular permeability via suppre-
sion of inflammatory signalling. Eur Respir J 2009; 33(3): 612–
24.
43. Murley JS, Kataoka Y, Weydert CJ, Oberley LW, Grdina DJ. Delayed
radioprotection by nuclear transcription factor ƪB-mediated in-
duction of manganese superoxide dismutase in human micro-
vascular endothelial cells after exposure to the free radical scav-
enger WR1065. Free Radic Biol Med 2006; 40(6): 1004–16.
44. Bolman Z, Akalin N, Koseogly MH, Demir S, Kadikoylu G, Atalay H,
et al. Effects of amifostine pre-treatment against adriamycin-
induced lipid peroxidation in rat heart. Haema 2003; 6: 61–4.
45. Jensen RA. Doxorubicin cardiotoxicity: contractile changes af-
ter long term treatment in the rat. J Pharmacol Exp Ther 1986;
236(1): 197–203.
46. Pelikan PCD, Weisfeld ML, Jacobus WE, Miceli MV, Bulkey BH,
Gerstebnlith G. Acute doxorubicin cardiotoxicity: functional
metabolic and morphologic alterations in the isolated, perfused
rat heart. J Cardiovasc Pharmacol 1986; 8(5): 1058–66.
47. Bhutia YD, Vijayaraghavan R, Pathak U. Analgesic and antiin-
flamatory activity of amifostine, DRDE-07, and their analogs
in mice. Indian J Pharmacol 2010; 42(1): 17–20.
48. Dragojevic-Simic V, Jacevic V, Dobric S, Djordjevic A, Bokonjic D ,
Bajcetic M, et al. Anti-inflammatory activity of fullerenol
C60(OH)24 nano-particles in a model of acute inflammation in
rats. Digest J Nanomater Biostr 2011; 6(2): P819–27.
Received on May 9, 2011.
Accepted on July 12, 2011.
OnLine-first November, 2012.